GeoVax Labs, Inc. cash flow to debt ratio of -2.55K% indicates that the company cannot generate enough cash to cover its debt over time. This level indicates weak financial health.

GeoVax Labs, Inc.'s free cash flow has increased -12.94% from $-24.70M last year to $-21.50M, signaling increasing performance

GeoVax Labs, Inc.'s debt to equity ratio is 0.18, which means that the company's assets are healthy financed, signaling financial stability.

GeoVax Labs, Inc. has insufficient data to evaluate this check.

GeoVax Labs, Inc. has a net cash position, so leverage is healthy.

GeoVax Labs, Inc. earns at least as much interest as it pays. Interest obligations are fully covered.

GeoVax Labs, Inc.'s profit margin has increased (-100.00%) in the last year from -631.98% to 0.00%, signaling increasing performance

GeoVax Labs, Inc.'s short-term assets of $5.31M exceed its short-term liabilities of $1.94M

GeoVax Labs, Inc.'s return on assets of 0.00% is lower than the 5.00% threshold, indicating inefficient asset utilization

GeoVax Labs, Inc.'s return on equity of -743.66%, is lower than 15.00%, indicating bad performance

GeoVax Labs, Inc.'s operating cash flow is lower than its net income, indicating that earnings may not be fully backed by cash generation

GeoVax Labs, Inc. had positive net income in only 0 out of 5 years, indicating unstable earnings

GeoVax Labs, Inc. has negative free cash flow, indicating the company is burning cash rather than generating it

GeoVax Labs, Inc. has negative free cash flow, indicating cash burn

GeoVax Labs, Inc.'s yearly earnings has increased -14.11% since last year from $-24.99M to $-21.46M, signaling increasing performance

GeoVax Labs, Inc.'s yearly revenue has decreased 100.00% since last year from $3.95M to $0.00, signaling decreasing performance

ROIC -985.20% (Source: FMP key-metrics). Below the 5% partial-credit threshold. Score: 0 of 2. The 5% and 10% cutoffs anchor to typical US weighted-average cost of capital. Below 5% indicates the company is not generating returns above its likely cost of capital under this definition of invested capital. Invested capital here includes equity, non-current liabilities (pension obligations, deferred taxes, lease obligations), and short-term debt. Cash is not subtracted. Companies with substantial float, lease portfolios, or cash holdings will score lower under this definition than under narrower operating-capital definitions. See methodology.

GeoVax Labs, Inc.'s 3-year revenue CAGR of 212.55% is positive, indicating growing revenue over the past 3 years

GeoVax Labs, Inc. had revenue growth in only 1 out of 5 years, indicating inconsistent revenue performance

GeoVax Labs, Inc. had positive ROE in only 0 out of 5 years, indicating inconsistent returns on equity

GeoVax Labs, Inc. is undervalued relative to its fair value price of 1.36M based on Discounted Cash Flow model

GeoVax Labs, Inc. has negative trailing-twelve-month earnings; this ratio is not meaningful and the check fails

GeoVax Labs, Inc. is undervalued relative to its fair value price of 2.21M based on EBITDA multiple model

GeoVax Labs, Inc. has negative or missing EBITDA, making EV/EBITDA ratio unreliable

GeoVax Labs, Inc. has insufficient data to evaluate this check.

GeoVax Labs, Inc. has negative trailing-twelve-month earnings; this ratio is not meaningful and the check fails

GeoVax Labs, Inc. has a price-to-book ratio of 1.95x, which is below the 5.00x threshold, indicating reasonable valuation relative to its book value

GeoVax Labs, Inc. has a price-to-sales ratio of 999.00x, which exceeds the 8.00x threshold, indicating the stock may be overvalued relative to its revenue